Evidence-based pharmacotherapy for personality disorders

International Journal of Neuropsychopharmacology

Volumn 14, Issue 9, 2011, Pages 1257-1288

  Ripoll, Luis H ^a   Triebwasser, Joseph ^a   Siever, Larry J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Avoidant personality disorder; borderline personality disorder; medication; psychopharmacology; schizotypal personality disorder

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; FLUOXETINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; LITHIUM CARBONATE; LOXAPINE SUCCINATE; MIANSERIN; OLANZAPINE; OXAZEPAM; PAROXETINE; PERGOLIDE; PHENELZINE; PHENYTOIN; RISPERIDONE; TIOTIXENE; TRANYLCYPROMINE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; PSYCHOTROPIC AGENT;

ARTICLE; AVOIDANT PERSONALITY DISORDER; BEDTIME DOSAGE; BORDERLINE STATE; CLINICAL FEATURE; COGNITION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPATHY; PSYCHOPHARMACOTHERAPY; SCHIZOTYPAL PERSONALITY DISORDER; SUICIDE ATTEMPT; EVIDENCE BASED MEDICINE; FEMALE; MALE; PERSONALITY DISORDER; REVIEW;

EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; PERSONALITY DISORDERS; PSYCHOTROPIC DRUGS;

EID: 84856071941     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000071     Document Type: Article

References (185)

1. Abraham PF, Calabrese JR (2008). Evidence-based pharmacologic treatment of borderline personality disorder : a shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of Affective Disorders 111, 21-30.
2. Akiskal HS (2004). Demystifying borderline personality : critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatrica Scandinavica 110, 401-407. (Pubitemid 39564090)
3. Alden LE, Paosa JM, Taylor CT, Ryder AG (2002). Avoidant personality disorder : current status and future directions. Journal of Personality Disorders 16, 1-29. (Pubitemid 34178263)
4. Aldenkamp AP, Arends J, Boorsma HPR, Diepman L, et al. (2002). Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 43, 19-26. (Pubitemid 34215448)
5. Allgulander C (1999). Paroxetine in social anxiety disorder : a randomized placebo-controlled study. Acta Psychiatrica Scandinavica 100, 193-198. (Pubitemid 29409085)
6. Allgulander C, Mangano R, Zhang J, Dahl AA, et al. (2004). Efficacy of venlafaxine ER in patients with social anxiety disorder : a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharmacology 19, 387-396. (Pubitemid 39172803)
7. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association.
8. APA (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry 158 (October supplement), 1-52.
9. Baldwin D, Bobes J, Stein DJ, Scharwachter I, et al. (1999). Paroxetine in social phobia/social anxiety disorder. Randomised double-blind, placebo-controlled study. Paroxetine Study. British Journal of Psychiatry 175, 120-126. (Pubitemid 29359373)
10. Barratt ES, Kent TA, Bryant SG, Felthous AR (1991). A controlled trial of phenytoin in impulsive aggression. Journal of Clinical Psychopharmacology 11, 388-389.
11. Barratt ES, Stanford MS, Felthous AR, Kent TA (1997). The effects of phenytoin on impulsive and pre-meditated aggression: a controlled study. Journal of Clinical Psychopharmacology 17, 341-349. (Pubitemid 27414389)
12. Battaglia J, Wolff TK, Wagner-Johnson DS, Rush AJ, et al. (1999). Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. International Clinical Psychopharmacology 14, 361-372. (Pubitemid 29531386)
13. Bender DS, Skodol AE (2007). Borderline personality as a self-other representational disturbance. Journal of Personality Disorders 21, 500-517. (Pubitemid 350006879)
14. Bergida H, Lenzenweger MF (2006). Schizotypy and sustained attention : confirming evidence from an adult community sample. Journal of Abnormal Psychology 115, 545-551. (Pubitemid 44763684)
15. Blair RJR (2005). Responding to the emotions of others : dissociating forms of empathy through the study of typical and psychiatric populations. Consciousness and Cognition 14, 698-718.
16. Blomhoff S, Haug TT, Hellstrom K, Holme I, et al. (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry 179, 23-30.
17. Bogenschutz MP, Nurnberg PH (2004). Olanzapine vs. placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 65, 104-109.
18. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, et al. (1999). Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder : an open-label trial. Journal of Clinical Psychiatry 60, 598-603. (Pubitemid 29451556)
19. Bolton S, Gunderson JG (1996). Distinguishing borderline personality disorder from bipolar disorder : differential diagnosis and implications. American Journal of Psychiatry 153, 1202-1207. (Pubitemid 26299842)
20. Brambilla P, Soloff PH, Sala M, Nicoletti MA, et al. (2004). Anatomical MRI study of borderline personality disorder patients. Psychiatry Research 131, 125-133. (Pubitemid 39094646)
21. Coccaro EF, Kavoussi RJ (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry 54, 1081-1088. (Pubitemid 27524373)
22. Coccaro EF, Kavoussi RJ, Hauger RL (1995). Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. International Clinical Psychopharmacology 10, 177-179.
23. Coccaro EF, Lee RJ, Kavoussi RJ (2009). A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. Journal of Clinical Psychiatry 70, 653-662.
24. Coccaro EF, Siever LJ, Klar HM, Maurer G, et al. (1989). Serotonergic studies in patients with affective and personality disorders : correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry 46, 587-599. (Pubitemid 19180336)
25. Cornelius JR, Soloff PH, Perel JM, Ulrich RF (1993). Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry 150, 1843-1848. (Pubitemid 23356578)
26. Cowdry RW, Gardner DL (1988). Pharmacotherapy of borderline personality disorder : alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry 45, 111-119. (Pubitemid 18052841)
27. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, et al. (2004b). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 118-125. (Pubitemid 38380834)
28. Davidson JR, Foa EB, Huppert JD, Keefe FJ, et al. (2004a). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 61, 1005-1013. (Pubitemid 39336534)
29. de la Fuente JM, Lotstra F (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology 4, 479-486.
30. Depue RA, Morrone-Strupinsky JV (2005). A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation. Behavioral and Brain Sciences 28, 313-395.
31. Deutsch H (1942). Some forms of emotional disturbance and their relationship to schizophrenia. Psychoanalytic Quarterly 11, 301-321.
32. Ekselius L, von Knorring L (1998). Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. International Clinical Psychopharmacology 13, 205-211. (Pubitemid 28470311)
33. Evenden J (1999). Impulsivity: a discussion of clinical and experimental findings. Journal of Psychopharmacology 13, 180-192. (Pubitemid 29276830)
34. Fahlen T (1995). Personality traits in social phobia, II : changes during drug treatment. Journal of Clinical Psychiatry 56, 569-573. (Pubitemid 26001767)
35. Faltus FJ (1984). The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. American Journal of Psychiatry 141, 802-803. (Pubitemid 14106373)
36. Fonagy P, Luyten P (2009). A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder. Development and Psychopathology 21, 1355-1381.
37. Frankenburg FR, Zanarini MC (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder : a double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry 63, 442-446. (Pubitemid 34507223)
38. Frankenburg FR, Zanarini MC (2006). Obesity and obesity-related illnesses in borderline patients. Journal of Personality Disorders 20, 71-80.
39. Gardner DL, Cowdry RW (1986a). Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology 6, 236-239. (Pubitemid 16004574)
40. Gardner DL, Cowdry RW (1986b). Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. American Journal of Psychiatry 143, 519-522. (Pubitemid 16119761)
41. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, et al. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo. Archives of General Psychiatry 43, 680-686. (Pubitemid 16094180)
42. Goodman M, New A, Siever L (2004). Trauma, genes, and the neurobiology of personality disorders. Annals of the New York Academy of Sciences 1032, 104-116. (Pubitemid 40298463)
43. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry 65, 432-441.
44. Griengl H, Sendera A, Dantendorfer K (2001). Naltrexone as a treatment of self-injurious behavior-a case report. Acta Psychiatrica Scandinavica 103, 234-236. (Pubitemid 32154357)
45. Hamazaki T, Sawazaki S, Itomura M, Asaoka E, et al. (1996). The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. Journal of Clinical Investigation 97, 1129-1133. (Pubitemid 26070593)
46. Hamazaki T, Thienprasert A, Kheovichai K, Samuhaseneetoo S, et al. (2002). The effect of docosahexaenoic acid on aggression in elderly Thai subjects-a placebo-controlled double-blind study. Nutritional Neuroscience 5, 37-41. (Pubitemid 34228992)
47. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, et al. (1998). Cognitive behavioral group therapy vs. phenelzine therapy for social phobia: 12-week outcome. Archives of General Psychiatry 55, 1133-1141. (Pubitemid 28558287)
48. Henry C, Mitropoulou V, New AS, Koenigsberg HW, et al. (2001). Affective instability and impulsivity in borderline personality and bipolar II disorders : similarities and differences. Journal of Psychiatric Research 35, 307-312. (Pubitemid 33000467)
49. Herpertz SC, Zanarini M, Schulz CS, Siever L, et al. (2007). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. World Journal of Biological Psychiatry 8, 212-244. (Pubitemid 350018476)
50. Higgins GA, Enderlin M, Haman M, Fletcher PJ (2003). The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berlin) 170, 309-319. (Pubitemid 37491611)
51. Hollander E, Allen A, Lopez RP, Bienstock CA, et al. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry 62, 199-203. (Pubitemid 32270095)
52. Hollander E, Swann AC, Coccaro EF, Jiang P, et al. (2005). Impact of trait impulsivity and state aggression on divalproex vs. placebo response in borderline personality disorder. American Journal of Psychiatry 162, 621-624. (Pubitemid 40343936)
53. Hollander E, Tracy KA, Swann AC, Coccaro EF, et al. (2003). Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28, 1185-1197.
54. Houston RJ, Bauer LO, Hesselbrock VM (2004). Effects of borderline personality disorder features and a family history of alcohol or drug dependence on P300 in adolescents. International Journal of Psychophysiology 53, 57-70. (Pubitemid 38686682)
55. Huband N, Ferriter M, Nathan R, Jones H (2010). Antiepileptics for aggression and associated impulsivity. Cochrane Database for Systematic Reviews. Issue 2, Art. No. CD003499. IMCTGMSP
56. Katschnig H (1997). The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience 247, 71-80.
57. Ingenhoven T, Lafay P, Rinne T, Passchier J, et al. (2010). Effectiveness of pharmacotherapy for severe personality disorders : meta-analyses of randomized controlled trials. Journal of Clinical Psychiatry 71, 14-25.
58. Jensen HV, Andersen J (1989). An open, noncomparative study of amoxapine in borderline disorders. Acta Psychiatrica Scandinavica 79, 89-93. (Pubitemid 19063030)
59. Juengling FD, Schmahl C, Hesslinger B, Ebert D, et al. (2003). Positron emission tomography in female patients with borderline personality disorder. Journal of Psychiatric Research 37, 109-115. (Pubitemid 36808473)
60. Kasper S, Stein DJ, Loft H, Nil R (2005). Escitalogram in the treatment of social anxiety disorder : randomised, placebo-controlled, flexible-dosage study. British Journal of Psychiatry 186, 222-226. (Pubitemid 40343816)
61. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, et al. (1995). Sertraline for social phobia: a double-blind, placebo-controlled crossover study. American Journal of Psychiatry 152, 1368-1371.
62. Kayser A, Robinson DS, Nies A, HowardD(1985). Response to phenelzine among depressed patients with features of hysteroid dysphoria. American Journal of Psychiatry 142, 486-488. (Pubitemid 15108214)
63. Keck P, Buffenstein A, Ferguson J, Feighner J, et al. (1998). Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder : a 4-week placebo-controlled trial. Psychopharmacology 140, 173-184. (Pubitemid 28538477)
64. Koenigsberg HW, Reynolds D, Goodman M, New AS, et al. (2003). Risperidone in the treatment of schizotypal personality disorder. Journal of Clinical Psychiatry 64, 628-634. (Pubitemid 36750138)
65. Lader M, Stender K, Burger V, Nil R (2004). Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder : randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety 19, 241-248. (Pubitemid 39014144)
66. Langdon R, Coltheart M (2004). Recognition of metaphor and irony in young adults : the impact of schizotypal personality traits. Psychiatry Research 125, 9-20. (Pubitemid 38210248)
67. Leiberich P, Nickel MK, Tritt K, Pedrosa Gil F (2008). Lamotrigine treatment of aggression in female borderline patients, part II : an 18-month follow-up. Journal of Psychopharmacology 22, 805-808.
68. Leone NF (1982). Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry 43, 148-150. (Pubitemid 12156641)
69. Lepola U, Bergtholdt B, St Lambert J, Davy KL, et al. (2004). Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry 65, 222-229.
70. Levitt JJ, Westin CF, Nestor PG, Estepar RS, et al. (2004). Shape of caudate nucleus and its cognitive correlates in neuroleptic-naïve schizotypal personality disorder. Biological Psychiatry 55, 177-184. (Pubitemid 38367721)
71. Lieb K, Vollm B, Rucker G, Timmer A, et al. (2010). Pharmacotherapy for borderline personality disorder : Cochrane systematic review of randomized trials. British Journal of Psychiatry 196, 4-12.
72. Lieb K, Zanarini MC, Schmahl C, Linehan MM, et al. (2004). Borderline personality disorder. Lancet 364, 453-461. (Pubitemid 39036894)
73. Liebowitz MR, Gelenberg AJ, Munjack D (2005a). Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 62, 190-198. (Pubitemid 40189136)
74. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, et al. (1999). Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression and Anxiety 10, 89-98.
75. Liebowitz MR, Klein DF (1981). Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatric Clinics of North America 4, 67-87. (Pubitemid 12170955)
76. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, et al. (2005b). A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 238-247. (Pubitemid 40314332)
77. Liebowitz MR, Stein MB, Tancer M, Carpenter D, et al. (2002). A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 63, 66-74. (Pubitemid 34113490)
78. Links PS, Steiner M, Boiago I, Irwin D (1990). Lithium therapy for borderline patients : preliminary findings. Journal of Personality Disorders 4, 173-181. (Pubitemid 20339898)
79. Lion JR (1979). Benzodiazepines in the treatment of aggressive patients. Journal of Clinical Psychiatry 40, 70-71. (Pubitemid 9111303)
80. Loew TH, Nickel MK (2008). Topiramate treatment of women with borderline personality disorder, part II : an open 18-month follow-up. Journal of Clinical Psychopharmacology 28, 355-357.
81. Loew TH, Nickel MK, Muehlbacher M, Kaplan P, et al. (2006). Topiramate treatment of women with borderline personality disorder : a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 26, 61-66. (Pubitemid 43167093)
82. Loranger AW, Sartorius N, Andreoli A, Berger P, et al. (1994). The international personality disorders examination. The world health organization/alcohol, drug abuse, and mental health administration international pilot study of personality disorders. Archives of General Psychiatry 51, 215-224. (Pubitemid 24081510)
83. Lott M, Greist JH, Jefferson JW, Kobak KA, et al. (1997). Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. Journal of Clinical Psychophamacology 17, 255-260. (Pubitemid 27312422)
84. Malone KM, Corbitt EM, Li S, Mann JJ (1996). Prolactin response to fenfluramine and suicide attempt lethality in major depression. British Journal of Psychiatry 168, 324-329.
85. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY (1991). Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry 148, 1064-1067.
86. Mattes JA (2005). Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 25, 575-579. (Pubitemid 41669053)
87. Mattes JA (2008). Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 310-315. (Pubitemid 351469275)
88. Mauchnik J, Schmahl C (2010). The latest neuroimaging findings in borderline personality disorder. Current Psychiatry Reports 12, 46-55.
89. McClure MM, Barch DM, Romero MJ, Minzenberg MJ, et al. (2007b). The effects of guanfacine on context-processing abnormalities in schizotypal personality disorder. Biological Psychiatry 61, 1157-1160. (Pubitemid 46669454)
90. McClure MM, Harvey PD, Goodman M, Triebwasser J, et al. (2010). Pergolide treatment of cognitive deficits associated with schizotypal personality disorder : continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 35, 1356-1362.
91. McClure MM, Romero MJ, Bowie CR, Reichenberg A, et al. (2007a). Visual-spatial learning and memory in schizotypal personality disorder : continued evidence for the importance of working memory in the schizophrenia spectrum. Archives of Clinical Neuropsychology 22, 109-116. (Pubitemid 46209596)
92. McGee MD (1997). Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry 58, 32-33. (Pubitemid 27089719)
93. Mehlman PT, Higley JD, Faucher I, Lilly AA, et al. (1994). Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates. American Journal of Psychiatry 151, 1485-1491. (Pubitemid 24301694)
94. Mercer D, Douglass AB, Links PS (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder : effectiveness for depression and anger symptoms. Journal of Personality Disorders 23, 156-174.
95. Minzenberg MJ, Grossman R, New AS, Mitropoulou V, et al. (2006). Blunted hormone responses to ipsapirone are associated with trait impulsivity in personality disorder patients. Neuropsychopharmacology 31, 197-203. (Pubitemid 43250956)
96. Montgomery SA, Montgomery D (1982). Pharmacological prevention of suicidal behavior. Journal of Affective Disorders 4, 291-298.
97. Montgomery SA, Nil R, Durr-Pal N, Loft H, et al. (2005). A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 1270-1278. (Pubitemid 41546506)
98. Montgomery SA, Roy D, Montgomery DB (1983). The prevention of recurrent suicidal acts. British Journal of Clinical Pharmacology 15, 183S-188S. (Pubitemid 13094492)
99. New AS, Hazlett EA, Buchsbaum MS, Goodman M, et al. (2002). Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to metachlorophenylpiperazine in impulsive aggression. Archives of General Psychiatry 59, 621-629. (Pubitemid 34747242)
100. New AS, Trestman R, Mitropoulou V, Benishay DS, et al. (1997). Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Research 69, 17-26. (Pubitemid 27139680)
101. New AS, Trestman R, Mitropoulou V, Goodman M, et al. (2004). Low prolactin response to fenfluramine in impulsive aggression. Journal of Psychiatric Research 38, 223-230. (Pubitemid 38299158)
102. Nickel MK, Loew TH (2008). Treatment of aggression with topiramate in male borderline patients, part II : 18-month follow-up. European Psychiatry 23, 115-117. (Pubitemid 351284510)
103. Nickel MK, Loew TH, Pedrosa Gil F (2007). Aripiprazole in treatment of borderline patients, part II : an 18-month follow-up. Psychopharmacology 191, 1023-1026. (Pubitemid 46399152)
104. Nickel MK, Muehlbacher M, Nickel C, Kettler C, et al. (2006). Aripiprazole in the treatment of patients with borderline personality disorder : a double-blind, placebo-controlled study. American Journal of Psychiatry 163, 833-838. (Pubitemid 44464531)
105. Nickel MK, Nickel C, Kaplan P, Lahmann C, et al. (2005). Treatment of aggression with topiramate in male borderline patients : a double-blind, placebo-controlled study. Biological Psychiatry 57, 495-499. (Pubitemid 40311984)
106. Nickel MK, Nickel C, Mitterlehner FO, Tritt K, et al. (2004). Topiramate treatment of aggression in female borderline personality disorder patients : a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 65, 1515-1519.
107. Noyes R, Moroz G, Davidson JR, Liebowitz MR, et al. (1997). Moclobemide in social phobia: a controlled dose-response trial. Journal of Clinical Psychopharmacology 17, 247-254. (Pubitemid 27312421)
108. Ogiso Y, Moriya N, Ikuta N, Maher-Nishizono A, et al. (1993). Relationship between clinical symptoms and EEG findings in borderline personality disorder. Japanese Journal of Psychiatry and Neurology 47, 37-46. (Pubitemid 23154929)
109. Oquendo MA, Krunic A, Parsey RV, Milak M, et al. (2005). Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder. Neuropsychopharmacology 30, 1163-1172. (Pubitemid 40720975)
110. Pande AC, Davidson JR, Jefferson JW, Janney CA, et al. (1999). Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of Clinical Psychopharmacology 19, 341-348. (Pubitemid 29344848)
111. Pande AC, Feltner DE, Jefferson JW, Davidson JR, et al. (2004). Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. Journal of Clinical Psychopharmacology 24, 141-149.
112. Parc S, McTigue K (1997). Working memory and the syndromes of schizotypal personality. Schizophrenia Research 29, 213-220. (Pubitemid 27431786)
113. Paris J (2004). Borderline or bipolar? Distinguishing borderline personality disorder from bipolar spectrum disorders. Harvard Review of Psychiatry 12, 140-145. (Pubitemid 38880158)
114. Paris J (2005). Borderline personality disorder. Canadian Medical Association Journal 172, 1579-1583. (Pubitemid 40839530)
115. Parsons B, Quitkin FM, McGrath PJ, Stewart JW, et al. (1989). Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacological Bulletin 25, 524-534. (Pubitemid 20137977)
116. Pascual JC, Oller S, Soler J, Barrachina J, et al. (2004). Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. Journal of Clinical Psychiatry 65, 1281-1283.
117. Pascual JC, Madre M, Soler J, Barrachina J, et al. (2006). Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 39, 117-118. (Pubitemid 43901627)
118. Pascual JC, Soler J, Puigdemont D, Perez-Egea R, et al. (2008). Ziprasidone in the treatment of borderline personality disorder : a double-blind, placebo-controlled, randomized study. Journal of Clinical Psychiatry 69, 603-608. (Pubitemid 351792335)
119. Peet M, Stokes C (2005). Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 65, 1051-1059. (Pubitemid 40840003)
120. Philipsen A, Richter H, Schmahl C, Peters J, et al. (2004a). Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry 65, 1414-1419.
121. Philipsen A, Schmahl C, Lieb K (2004b). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 37, 196-199. (Pubitemid 39286920)
122. Pickup GJ (2006). Theory of mind and its relation to schizotypy. Cognitive Neuropsychiatry 11, 177-192. (Pubitemid 43253994)
123. Pitchot W, Hansenne M, Pinto E, Reggers J, et al. (2005). 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biological Psychiatry 58, 854-858. (Pubitemid 41790712)
124. Placidi GP, Oquendo MA, Malone KM, Huang YY, et al. (2001). Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biological Psychiatry 50, 783-791. (Pubitemid 33086766)
125. Posner MI, Rothbart MK, Vizueta N, Levy KN, et al. (2002). Attentional mechanisms of borderline personality disorder. Proceedings of the National Academy of Sciences USA 99, 16366-16370. (Pubitemid 35469146)
126. Prossin AR, Love TM, Koeppe RA, Zubieta JK, et al. (2010). Dysregulation of regional endogenous opioid function in borderline personality disorder. American Journal of Psychiatry 167, 925-933.
127. Reich DB, Zanarini MC, Bieri KA (2009). A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology 24, 270-275.
128. Reich J (2002). Drug treatment of personality disorder traits. Psychiatric Annals 32, 590-596. (Pubitemid 37346786)
129. Rickels K, Mangano R, Khan A (2004). A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 488-496. (Pubitemid 39274203)
130. Rifkin A, Quitkin F, Carrillo C, Blumberg AG, et al. (1972). Lithium carbonate in emotionally unstable character disorder. Archives of General Psychiatry 27, 519-523.
131. Rinne T, van den Brink W, Wouters L, van Dyck R (2002). SSRI treatment of borderline personality disorder : a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry 159, 2048-2054. (Pubitemid 35423864)
132. Roth AS, Rostroff RB, Hoffman RE (1996). Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial. Journal of Clinical Psychiatry 57, 233-237. (Pubitemid 26230644)
133. Rusch N, van Elst LT, Ludaescher P, Wilke M, et al. (2003). A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage 20, 385-392. (Pubitemid 37188526)
134. Russ MJ, Campbell SS, Kakuma T, Harrison K, et al. (1991). EEG theta activity and pain insensitivity in self-injurious borderline patients. Psychiatry Research 89, 201-214.
135. Salzman C, Wolfson AN, Schatzberg A, Looper J, et al. (1995). Effects of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology 15, 23-29.
136. Samuelsson M, Jokinen J, Nordstrom AL, Nordstrom P (2006). CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatrica Scandinavica 113, 44-47. (Pubitemid 43339088)
137. Saper JR (2000). Borderline personality, opioids, and naltrexone. Headache 40, 765-766.
138. Schneier FR, Gortz D, Campeas R, Fallon B, et al. (1998). Placebo-controlled trial of moclobemide in social phobia. British Journal of Psychiatry 172, 70-77. (Pubitemid 28122531)
139. Schulz SC, Zanarini MC, Bateman A, Bohus M, et al. (2008). Olanzapine for the treatment of borderline personality disorder : variable-dose 12-week randomized double-blind placebo-controlled study. British Journal of Psychiatry 193, 485-492.
140. Serban G, Siegel S (1984). Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry 141, 1455-1458. (Pubitemid 14023951)
141. Shafti SS, Shahveisi B (2010). Olanzapine vs. haloperidol in the management of borderline personality disorder : a randomized double-blind trial. Journal of Clinical Psychopharmacology 30, 44-47.
142. Sheard MH (1971). Effect of lithium on human aggression. Nature 230, 113-114.
143. Sheard MH, Marini JL, Bridges CI, Wagner E (1976). The effect of lithium on impulsive aggressive behavior in man. American Journal of Psychiatry 133, 1409-1413.
144. Siever LJ, Buchsbaum MS, New AS, Spiegel-Cohen J, et al. (1999). D,L-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emissiontomography.Neuropsychopharmacology20, 413-423. (Pubitemid 29123869)
145. Siever LJ, Davis KL (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry 148, 1647-1658.
146. Siever LJ, Davis KL (2004). The pathophysiology of schizophrenia disorders : perspectives from the spectrum. American Journal of Psychiatry 161, 398-413. (Pubitemid 38326093)
147. Simeon D, Stanley B, Frances A, Mann JJ, et al. (1992). Self-mutilation in personality disorders: psychological and biological correlates. American Journal of Psychiatry 149, 221-226.
148. Simpson EB, Yen S, Costello E, Rosen K, et al. (2004). Combined
149. Skodol AE, Gunderson JG, Shea MT, McGlashan TH, et al. (2005). The collaborative longitudinal personality disorders study (CLPS): overview and implications. Journal of Personality Disorders 19, 487-504. (Pubitemid 41618523)
150. Smith DJ, Muir WJ, Blackwood DH (2004). Is borderline personality disorder part of the bipolar spectrum? Harvard Review of Psychiatry 12, 133-139. (Pubitemid 38880157)
151. Soderstrom H, Foresman A (2004). Elevated triiodothyronine in psychopathy-possible physiological mechanisms. Journal of Neural Transmission 111, 739-744. (Pubitemid 38716553)
152. Soler J, Pascual JC, Campins J, Barrachina J, et al. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry 162, 1221-1224. (Pubitemid 40770712)
153. Soloff PH, Cornelius J, George A, Nathan S, et al. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry 50, 377-385. (Pubitemid 23143127)
154. Soloff PH, George A, Nathan RS, Schulz PM, et al. (1986a). Paradoxical effects of amitryptiline on borderline patients. American Journal of Psychiatry 143, 1603-1605. (Pubitemid 17196209)
155. Soloff PH, George A, Nathan RS, Schulz PM, et al. (1986b). Amitryptiline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacology Bulletin 22, 177-182. (Pubitemid 16101352)
156. Soloff PH, George A, Nathan RS, Schulz PM, et al. (1986c). Progress in pharmacotherapy of borderline disorders. Archives of General Psychiatry 43, 691-697.
157. Soloff PH, George A, Nathan RS, Schulz PM, et al. (1987). Behavioral dyscontrol in borderline patients treated with amitryptiline. Psychopharmacology Bulletin 23, 177-181. (Pubitemid 17111690)
158. Soloff PH, George A, Nathan RS, Schulz PM, et al. (1989). Amitryptiline vs. haloperidol in borderlines : final outcomes and predictors of response. Journal of Clinical Psychopharmacology 9, 238-246. (Pubitemid 19198957)
159. Southwick SM, Bremner JD, Rasmusson A, Morgan CA, et al. (1999). Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biological Psychiatry 46, 1192-1204. (Pubitemid 30114437)
160. Stanley B, Siever LJ (2010). The interpersonal dimension of borderline personality disorder : toward a neuropeptide model. American Journal of Psychiatry 167, 24-39.
161. Stein DJ, Versiani M, Hair T, Kumar R (2002). Efficacy of paroxetine for relapse prevention in social anxiety disorder. Archives of General Psychiatry 59, 1111-1118. (Pubitemid 35424021)
162. Stein MB, Fyer AJ, Davidson JR, Pollack MH, et al. (1999). Fluvoxamine treatment of social phobia (social anxiety disorder) : a double-blind, placebo-controlled study. American Journal of Psychiatry 156, 756-760. (Pubitemid 29220075)
163. Stein MB, LiebowitzMR, Lydiard RB, Pitts CD, et al. (1998). Paroxetine treatment of gereralized social phobia (social anxiety disorder) : a randomized controlled trial. Journal of the American Medical Association 280, 708-713. (Pubitemid 28405295)
164. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, et al. (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder : a 6-month randomized controlled trial. Psychopharmalogy 177, 280-288. (Pubitemid 40137288)
165. Strawn JR, Geracioti TD (2008). Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depression and Anxiety 25, 260-271. (Pubitemid 351499905)
166. Tandon R (2000). Introduction: ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics. British Journal of Clinical Pharmacology 49(Suppl. 1), 1S-3S.
167. Thurauf NJ, Washeim HA (2000). The effects of exogenous analgesia in a patient with borderline personality disorder (BPD) and severe self-injurious behavior. European Journal of Pain 4, 107-109. (Pubitemid 30230800)
168. Traskman L, Asberg M, Bertilsson L, Sjostrand L (1981). Monoamine metabolites in CSF and suicidal behavior. Archives of General Psychiatry 38, 631-636. (Pubitemid 11064819)
169. Tritt K, Nickel C, Lahmann C, Leiberich PK, et al. (2005). Lamotrigine treatment of aggression in female borderline patients : a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology 19, 287-291. (Pubitemid 40694947)
170. van Ameringen M, Oakman J, Mancini C, Pipe B, et al. (2004). Predictors of response in generalized social phobia: effect of age of onset. Journal of Clinical Psychopharmacology 24, 42-48. (Pubitemid 38134165)
171. van Ameringen MA, Lane RM, Walker JR, Bowen RC, et al. (2001). Sertraline treatment of generalized social phobia: a 20-week, doubleblind, placebo-controlled study. American Journal of Psychiatry 158, 275-281. (Pubitemid 32116525)
172. van Vliet IM, den Boer JA, Westenberg HG (1994). Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berlin) 115, 128-134. (Pubitemid 24207772)
173. Verkes RJ, van der Mast RC, Hengeveld MW, Tuyl JP, et al. (1998). Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry 155, 543-547. (Pubitemid 28207452)
174. Versiani M, Nardi AE, Mundim FD, Alves AB, et al. (1992). Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry 161, 353-360.
175. Virkkunen M, Rawlings R, Tokola R, Poland RE, et al. (1994). CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Archives of General Psychiatry 51, 20-27. (Pubitemid 24028994)
176. Welch SS, LinehanMM(2002).High-risk situations associated with parasuicide and drug use in borderline personality disorder. Journal of Personality Disorders 16, 561-569. (Pubitemid 36176972)
177. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, et al. (2002). The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. Journal of Clinical Psychopharmacology 22, 206-210. (Pubitemid 34289397)
178. Winstanley CA, Theobald DE, Dalley JW, Glennon JC, et al. (2004). 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity. Interactions with global 5-HT depletion. Psychopharmacology (Berlin) 176, 376-385.
179. Zanarini MC, Frankenburg FR (2001). Olanzapine treatment of female borderline personality disorder patients : a double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry 62, 849-854. (Pubitemid 33131170)
180. Zanarini MC, Frankenburg FR (2003). Omega-3 fatty acid treatment of women with borderline personality disorder : a double-blind, placebo-controlled pilot study. American Journal of Psychiatry 160, 167-169. (Pubitemid 36042442)
181. Zanarini MC, Frankenburg FR, Hennen J, Reich DB, et al. (2004a). Axis I comorbidity of borderline personality disorder : Description of six-year course and prediction to time-to-remission. American Journal of Psychiatry 161, 2108-2114. (Pubitemid 39441413)
182. Zanarini MC, Frankenburg FR, Parachini EA (2004b). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry 7, 903-907.
183. Zanarini MC, Frankenburg FR, Vujanovic AA, Hennen J, et al. (2004c). Axis II comorbidity of borderline personality disorder : Description of six-year course and prediction to time-to-remission. Acta Psychiatrica Scandinavica 110, 416-420. (Pubitemid 39564092)
184. Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL (1990). Discriminating borderline personality disorder from other axis II disorders. American Journal of Psychiatry 147, 161-167. (Pubitemid 20060466)
185. Ziegenhorn AA, Roepke S, Schommer NC, Merkl A, et al. (2009). Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder : a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 29, 170-173.